Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.

Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N.

Br J Cancer. 2006 Apr 10;94(7):1000-6.

2.

Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.

Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C.

AIDS. 2007 Jun 19;21(10):1245-52.

PMID:
17545700
3.

Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.

Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, Mermin J, Kaharuza F.

HIV Med. 2012 Mar;13(3):166-71. doi: 10.1111/j.1468-1293.2011.00955.x. Epub 2011 Nov 24.

4.

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.

Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthé H, de Truchis P, Zucman D, Rouveix E, Saiag P.

AIDS. 2000 May 26;14(8):987-93.

PMID:
10853980
5.

Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.

Cattelan AM, Calabrò ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M, Gasperini P, Zanchetta M, Cadrobbi P, Monfardini S, Chieco-Bianchi L.

Int J Oncol. 2005 Sep;27(3):779-85.

PMID:
16077928
6.

Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.

Lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K, Mauss S, Rockstroh JK; German Clinical AIDS Working Group (KAAD).

Infection. 2005 Jun;33(3):140-7.

PMID:
15940415
7.

AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.

Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Mena M, Tavio M, Vaccher E, D'Arminio Monforte A, Tirelli U; AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals.

J Clin Oncol. 2003 Aug 1;21(15):2876-82.

PMID:
12885804
9.

Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.

Cattelan AM, Calabrò ML, Gasperini P, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, Chieco-Bianchi L.

J Natl Cancer Inst Monogr. 2001;(28):44-9.

PMID:
11158206
10.

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.

Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B.

AIDS. 1999 Oct 22;13(15):2105-11.

PMID:
10546864
11.

Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.

Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, Calvez V, Gotch F, Boshoff C, Gazzard B.

J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):384-90.

PMID:
12447008
12.

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.

Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Bower M, Gazzard B.

AIDS. 2003 Jul 25;17(11):F17-22.

PMID:
12853764
13.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
14.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
15.

Multicentric Castleman's disease in HIV infection: a systematic review of the literature.

Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A.

AIDS Rev. 2008 Jan-Mar;10(1):25-35. Review.

PMID:
18385778
16.

Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.

Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, Copas A, Boshoff C.

AIDS. 2004 Feb 20;18(3):485-93.

PMID:
15090801
17.

Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.

Cattelan AM, Calabro ML, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, Chieco-Bianchi L.

Eur J Cancer. 1999 Dec;35(13):1809-15.

PMID:
10673996
18.

Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan.

Lin CY, Chen MY, Hsieh SM, Sheng WH, Sun HY, Lo YC, Hung CC, Chang SC.

J Microbiol Immunol Infect. 2009 Jun;42(3):227-33.

PMID:
19812856
19.

Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.

Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, Talamini R, Pagano G, Montroni M, Cinelli R, Vaccher E, D'Arminio Monforte A, Tirelli U; GICAT; ICONA.

Cancer. 2003 Dec 1;98(11):2440-6.

20.

Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.

Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2007 Mar;8(2):75-9.

Supplemental Content

Support Center